9月14日，三生制药盘中上涨5.31%，报16.26港元，成交额1.38亿港元。
消息面上，公司近期持续加大回购力度，9月10日单日斥资约6263万港元回购400万股，9月11日再度回购19万股；执行董事兼主席娄竞于9月7日以每股16.00港元增持49万股，涉资约784万港元，好仓比例升至21.13%。此外，公司核心品种SSGJ-707与辉瑞的全球临床合作持续推进，多家券商维持正面评级，目标价在30港元以上，当前股价隐含较大上行空间。生物科技板块今日整体走强，康方生物涨6.7%、科伦博泰生物涨3.53%，板块情绪亦构成支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.